S-606001 has the potential to become the first oral substrate reduction therapy for Pompe diseaseOSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results